The 340B drug pricing program has entered a new era of scrutiny, with pharmaceutical manufacturers, legislators, and safety-net providers all focused on program integrity. As covered entities navigate complex administrative dispute resolution processes and increasing oversight, maintaining ethical standards has never been more crucial for 340B program participants who dispense discounted drugs to eligible patients and provide comprehensive services.
Edward Vargas, founder of Virtue 340B, emphasizes this point: "It's always important to know when to say no. If it's difficult for an independent, unbiased party to infer that your covered entity is maintaining responsibility of care and meeting the requirements of the 340B statute, then it probably shouldn't be captured." Read More >
Since our inception in November 2022, Virtue has swiftly risen as a trailblazer in 340B compliance. We perform mock audits that simulate HRSA's rigorous reviews, helping covered entities identify risks and areas of non-compliance before actual audits. Our tailored approach, driven by seasoned healthcare professionals and 340B experts, evaluates program operations, policies, and controls. We ensure integrity and transparency by adhering to the International Standards for Professional Internal Auditing. Offering top-tier audit services at competitive rates, we make comprehensive 340B compliance accessible, transforming compliance challenges into manageable steps and optimizing program performance. Our commitment to excellence and expansion remains unwavering as we strive to become the best-in-class provider in the 340B industry.
